Peptide therapy TikTok claims: separating hype from evidence

What's this video probably claiming?

Creators in the peptide therapy space on TikTok tend to follow a predictable script. Given @peptastic7's category focus on bioactive peptides including BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, MK-677, semax, and selank, this video is almost certainly promoting one or more of these compounds as tools for accelerated recovery, anti-aging, enhanced growth hormone output, or cognitive performance. The framing is usually personal testimonial dressed up with just enough technical language to sound credible. Common claims in this space include things like "BPC-157 healed my tendon in two weeks," "ipamorelin gives you growth hormone pulses without the sides," or "MK-677 is basically HGH without the needle." These videos rarely distinguish between rat studies and human trials, and they almost never mention that most of these peptides are not FDA-approved for human use and exist in a regulatory gray zone that the FDA has been tightening since 2023.

What does the science actually show?

The honest answer is: mixed signals and a lot of rodent data. BPC-157 has shown genuine wound-healing and gastroprotective effects in animal models, with Sikiric et al. (2018, Current Pharmaceutical Design) documenting consistent results across multiple injury types in rats. But there are zero completed randomized controlled trials in humans as of 2024. TB-500 (thymosin beta-4) has similarly promising preclinical data for cardiac and musculoskeletal repair, but human evidence is limited to one small phase II trial in cardiac patients (Goldstein et al., 2012, Annals of the New York Academy of Sciences). CJC-1295 and ipamorelin as a stack do produce measurable increases in growth hormone and IGF-1 in humans. A 2006 study by Teichman et al. (Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 increased mean IGF-1 levels by 28-43% over 28 days. Whether that translates to body composition or recovery benefits in otherwise healthy adults is a separate question the literature has not cleanly answered.

Where does the social media noise diverge from clinical reality?

The gap is wide. TikTok peptide content systematically overstates certainty. A creator saying BPC-157 "repairs tendons" is extrapolating from rat tendon studies to human clinical outcomes, which is not a small leap. Animal models for tendon healing do not translate reliably to humans, as anyone who followed the platelet-rich plasma hype cycle of the 2010s knows. MK-677 is a particularly egregious example of misrepresentation. It is not a peptide, it is a ghrelin mimetic and orally active growth hormone secretagogue. Calling it "peptide therapy" is technically inaccurate. More importantly, MK-677 at 25 mg/day has been associated with increased fasting glucose, insulin resistance, and edema in trials (Nass et al., 2008, Annals of Internal Medicine). That information does not make it into most TikTok videos. Semax and selank, popular in nootropic communities, have almost no peer-reviewed English-language literature. Most published research is Russian and has not been independently replicated in Western trials.

What should you actually know?

If you are considering any of these compounds, a few things matter more than anything a short-form video can tell you. First, the FDA placed BPC-157 and TB-500 on its list of bulk drug substances that cannot be used in compounding as of 2023, meaning sourcing them from compounding pharmacies in the US is now legally complicated. Second, the peptides that do have legitimate clinical pathways, like growth hormone-releasing peptides, require physician oversight and proper lab work to use responsibly. IGF-1 levels, fasting glucose, and thyroid panels are baseline monitoring that no responsible provider skips. Third, quality control on gray-market peptide products is genuinely poor. A 2022 analysis by Catlin et al. found significant dosing inaccuracies and contamination in commercially available peptide products not subject to pharmaceutical manufacturing standards. The right question is not whether these compounds are interesting scientifically. Some of them are. The right question is whether the evidence justifies the risk profile at your specific health baseline, which is something only a clinician who knows your labs can answer.